Hikma Pharmaceuticals Regulatory News (HIK)

Block Listing of Shares

Hikma Pharmaceuticals PLC

LONDON, 9 March 2018 - The Board of Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (LEI: 549300BNS685UXH4JI75) (NASDAQ: HIK), announces that it has made a block listing application to the Financial Conduct Authority and the London Stock Exchange plc for a total of 2,000,000 ordinary shares of 10p each in the capital of the Company to be admitted to the Official List of the UK Listing Authority. It is expected that admission will be granted on 12 March 2018.

The shares, when issued, will be issued fully paid and rank pari passu in all respects with the existing issued ordinary shares of the Company. The shares will be issued pursuant to the vesting of shares under the Hikma Pharmaceuticals PLC 2009 Management Incentive Plan and the 2014 Executive Incentive Plan (the "Plans"). Participants in the Plans have or will become entitled to these shares following the vesting of the shares.

- ENDS -

Enquiries

About Hikma

Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: 'Injectables,' 'Generics' and 'Branded,' based primarily in the Middle East and North Africa (MENA) region, where it is a market leader, the United States and Europe. In 2016, Hikma achieved revenues of $1,950 million and profit attributable to shareholders of $155 million.